APA (7th ed.) Citation

Li, G., Li, X., Yin, R., Feng, M., Zuo, J., Wei, S., . . . Chen, Y. (2024). Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer. Gynecologic Oncology, 191, 165. https://doi.org/10.1016/j.ygyno.2024.10.001

Chicago Style (17th ed.) Citation

Li, Guiling, et al. "Phase II Study of Enlonstobart (SG001), a Novel PD-1 Inhibitor in Patients with PD-L1 Positive Recurrent/metastatic Cervical Cancer." Gynecologic Oncology 191 (2024): 165. https://doi.org/10.1016/j.ygyno.2024.10.001.

MLA (9th ed.) Citation

Li, Guiling, et al. "Phase II Study of Enlonstobart (SG001), a Novel PD-1 Inhibitor in Patients with PD-L1 Positive Recurrent/metastatic Cervical Cancer." Gynecologic Oncology, vol. 191, 2024, p. 165, https://doi.org/10.1016/j.ygyno.2024.10.001.